World Health Organization, New Delhi, India.
Int J Tuberc Lung Dis. 2011 Mar;15(3):358-62.
To measure the economic costs and benefits of scaling up tuberculosis (TB) control under the Revised National Tuberculosis Control Programme (RNTCP) in India.
Modelling based on country-level programme and epidemiological data from 1997 to 2006.
The scale-up of TB control in India has resulted in a total health benefit of 29.2 million disability-adjusted life years (DALYs), including 1.3 million deaths averted. In 2006, the burden of TB measured in terms of DALYs lost would have been 1.8 times higher in the absence of the programme. The total gain in economic well-being from TB control is estimated at US$88.1 billion over the 1997-2006 10-year period. Total public expenditure on TB control over this period amounted to US$768 million, with the RNTCP accounting for US$299 million and other health sector costs accounting for US$469 million. The cost of TB control averaged just US$26 per DALY gained over 1997-2006 and generated a return of US$115 per dollar spent.
The scale-up of TB control has been a very cost-effective strategy for improving the health status of India's population, while the return on investment has been exceptional from a societal perspective.
衡量印度强化全国结核病控制规划（RNTCP）下结核病控制的经济成本和效益。
基于 1997 年至 2006 年的国家级规划和流行病学数据进行建模。
印度结核病控制的扩大化带来了 2920 万残疾调整生命年（DALY）的总健康效益，包括避免了 130 万人死亡。如果没有该规划，2006 年衡量 DALY 损失的结核病负担将高出 1.8 倍。1997-2006 年 10 年间，结核病控制带来的经济福祉总增益估计为 881 亿美元。在此期间，用于结核病控制的总公共支出为 7.68 亿美元，其中 RNTCP 占 2.99 亿美元，其他卫生部门支出占 4.69 亿美元。结核病控制的平均成本仅为每获得一个 DALY 增加 26 美元，投资回报率从社会角度来看非常出色。
强化结核病控制是改善印度人口健康状况的一项极具成本效益的策略，从社会角度来看，投资回报率也非常高。
